Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Tax Provisions: 2013-2025

Historic Tax Provisions for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $4.2 million.

  • Amphastar Pharmaceuticals' Tax Provisions fell 42.61% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.2 million, marking a year-over-year decrease of 2.41%. This contributed to the annual value of $46.8 million for FY2024, which is 2.46% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Tax Provisions is $4.2 million, which was down 49.87% from $8.3 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Tax Provisions ranged from a high of $23.2 million in Q4 2022 and a low of $1.2 million during Q1 2021.
  • In the last 3 years, Amphastar Pharmaceuticals' Tax Provisions had a median value of $7.3 million in 2024 and averaged $10.0 million.
  • Data for Amphastar Pharmaceuticals' Tax Provisions shows a peak YoY increase of 7,560.00% (in 2021) and a maximum YoY decrease of 49.34% (in 2021) over the last 5 years.
  • Amphastar Pharmaceuticals' Tax Provisions (Quarterly) stood at $7.2 million in 2021, then soared by 222.06% to $23.2 million in 2022, then dropped by 20.02% to $18.5 million in 2023, then grew by 24.88% to $23.1 million in 2024, then crashed by 42.61% to $4.2 million in 2025.
  • Its last three reported values are $4.2 million in Q3 2025, $8.3 million for Q2 2025, and $5.6 million during Q1 2025.